Mesoblast Secures FDA Clearance for 76-Patient Phase III Ryoncil Trial in DMD
Mesoblast gained FDA IND clearance to initiate a Phase III trial of Ryoncil in Duchenne muscular dystrophy, enrolling 76 boys aged 5–9 with seven 2×10^6 cells/kg infusions over nine months. Study’s primary endpoint is time-to-stand at nine months, leveraging Ryoncil’s anti-inflammatory mechanism to preserve muscle function in 15,000 DMD patients.
1. FDA Grants IND Clearance for Ryoncil Trial
Mesoblast has received Investigational New Drug clearance from the FDA to proceed directly to a registrational Phase III trial of Ryoncil in Duchenne muscular dystrophy, marking a pivotal regulatory milestone for the cellular therapy.
2. Trial Design and Endpoints
The randomized, placebo-controlled study will enroll 76 boys aged 5–9, administering seven infusions of 2×10^6 cells/kg over nine months, with time-to-stand at nine months serving as the primary efficacy endpoint.
3. Collaboration with Parent Project Muscular Dystrophy
Mesoblast is partnering with Parent Project Muscular Dystrophy to identify and engage eligible patients, leveraging community networks to ensure timely recruitment and trial awareness among the estimated 15,000 U.S. DMD population.
4. Anti-Inflammatory Strategy and Potential Impact
Ryoncil’s mesenchymal stromal cell therapy targets the inflammatory cascade driving muscle degeneration in DMD, aiming to preserve ambulatory function and alter disease progression in a condition currently lacking curative treatments.